MRM Health NV announced that it has received 14,250,000 in an equity round of funding on February 19, 2020. The transaction will include participation from new investor DuPont Nutrition & Biosciences through DuPont de Nemours, Inc., Qbic II, a fund managed by QBIC Venture Partners, and VIB BV., and returning investors, Ackermans & Van Haaren NV for 4,000,000 and more than 15% stake, and MRM Technologies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
79.91 USD | +3.02% | +1.46% | +3.87% |
05-17 | DuPont: benefits from positive analysis by Jefferies | CF |
05-17 | DUPONT : Jefferies raises its opinion | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.87% | 33.41B | |
-1.30% | 75B | |
+0.19% | 47.43B | |
+11.03% | 18.24B | |
+11.76% | 11.8B | |
+1.70% | 10.97B | |
-16.29% | 10.93B | |
-0.10% | 9.26B | |
-8.12% | 8.11B | |
-5.62% | 7.46B |
- Stock Market
- Equities
- DD Stock
- News DuPont de Nemours, Inc.
- MRM Health NV announced that it has received €14.25 million in funding from DuPont de Nemours, Inc., Ackermans & Van Haaren NV, VIB BV, QBIC Venture Partners, MRM Technologies N.V.